The Australian multicentre double-blind comparative study of remoxipride and thioridazine in schizophrenia

Keks, N., McGrath, J., Lambert, T., Catts, S., Vaddadi, K., Burrows, G., Varghese, F., George, T., Hustig, H., Burnett, P., Kerr, K., Zorbas, A., Hill, C., Stedman, T., Johnson, G., Leibert, B., Copolov, D., Mackenzie, M. and Dillenbeck, C. (1994) The Australian multicentre double-blind comparative study of remoxipride and thioridazine in schizophrenia. Acta Psychiatrica Scandinavica, 90 5: 358-365. doi:10.1111/j.1600-0447.1994.tb01607.x


Author Keks, N.
McGrath, J.
Lambert, T.
Catts, S.
Vaddadi, K.
Burrows, G.
Varghese, F.
George, T.
Hustig, H.
Burnett, P.
Kerr, K.
Zorbas, A.
Hill, C.
Stedman, T.
Johnson, G.
Leibert, B.
Copolov, D.
Mackenzie, M.
Dillenbeck, C.
Title The Australian multicentre double-blind comparative study of remoxipride and thioridazine in schizophrenia
Journal name Acta Psychiatrica Scandinavica   Check publisher's open access policy
ISSN 0001-690X
1600-0447
Publication date 1994-11-01
Sub-type Article (original research)
DOI 10.1111/j.1600-0447.1994.tb01607.x
Volume 90
Issue 5
Start page 358
End page 365
Total pages 8
Place of publication Malden, MA, United States
Publisher Wiley-Blackwell
Language eng
Abstract A double-blind, randomized study of parallel group design comparing remoxipride and thioridazine (dose range 150-600 mg/day of either drug) was undertaken at 11 Australian centres. A total of 144 patients (remoxipride = 73, thioridazine = 71) with DSM-III-R schizophrenia or schizophreniform disorder commenced the study, and 89 patients (remoxipride = 45, thioridazine = 44) completed the 6 weeks of the trial. The mean daily doses at last rating were 404 mg (remoxipride) and 378 mg (thioridazine). Initial Brief Psychiatric Rating Scale scores decreased by a mean 8.7 points in both remoxipride and thioridazine groups. Equivalent treatment responses were also confirmed by Clinical Global Impression. During the study, sedatives or hypnotics were needed by 68% of the remoxipride patients and 51% of the thioridazine patients. Thioridazine was associated with more postural hypotension, drowsiness, increased sleep, headache, dizziness on rising, dry mouth, sexual dysfunction and weight gain, while remoxipride patients reported more insomnia. There were no differences between remoxipride and thioridazine on dystonia, hypokinesia, dyskinesia, rigidity and akathisia. The results indicate that remoxipride has similar antipsychotic efficacy to thioridazine but causes fewer side effects.
Keyword Neuroleptic drug
Remoxipride
Schizophrenia
Thioridazine
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: Queensland Brain Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 22 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 22 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 10 Mar 2011, 01:34:25 EST